Lumares Strategy
Scientific Insight. Integrated Strategy. Value-led Impact
Lumares Strategy delivers deep scientific expertise, strategic leadership, and senior-level advisory across the full product lifecycle - from early development through launch, growth and transformation.
​
We work with biotech, pharma, investors, and healthcare innovators to integrate science with corporate and clinical strategy - strategising measurable scientific impact, driving business-critical outcomes, and aligning business critical decisions.
​
We provide board-level and scientific advisory, executive medical strategy, and fractional leadership to drive launches, pivots and transformation at pace.
Who We Are
Scientific Insight. Integrated Strategy. Value-led Impact
Lumares Strategy is built on decades of senior in-house global leadership in pharma and biotech, anchored by deep scientific expertise and a recognised thought leader with expertise across multiple therapy areas.
​
We are not a typical agency or consultancy. We deliver agile, senior-led medical strategy and board-level advisory to executives, investors, funds, and healthcare leaders.
Our proven track record includes high stakes launches delivered at record pace, unprecedented organisational builds in Medical Affairs, and strategic pivots across diverse therapeutic areas - always aligned to corporate strategy and growth.
​
Our proprietary Value Impact Framework drives scientific credibility, stakeholder trust, and measurable outcomes aligned with corporate priorities.
Our Expertise
Scientific Insight. Integrated Strategy. Value-led Impact.
Lumares Strategy provides tailored strategic consultancy services to optimise operations, make business critical investment decisions and drive growth in the biotech/pharma industry. Our tailored solutions open up new opportunities and accelerate business expansion and bridge scientific insight, clinical evidence, and business objectives.
Strategic Consulting & Advisory
Board-Level & Science-Driven Strategy for End-to-End Success
We design end-to-end Medical Strategy from early stage development, prior to asset identification, right across the full product lifecycle - integrating scientific rigour, clinical evidence and corporate objectives - enhancing product positioning, market readiness, and strategic clarity.
​
Our deep scientific expertise spans multiple therapy areas - from neurology to cardio-metabolics, immunology, oncology, gene therapy, RNA therapeutics, and infectious diseases.
Service Menu:
-
End-to-End Medical Strategy (asset lifecycle design incl. evidence and stakeholder frameworks)
-
Pipeline & Portfolio Prioritisation (go/no-go decisions, indication strategy, rationalisation)
-
Target Product Profile & Development Hypothesis (strategic positioning in areas of highest unmet need)
-
Scientific–Corporate–Investor Alignment (integrating science with IR, corporate communications, and regulatory expectations)
-
Medical Representation to Payers & Regulators (medical voice with payers, health technology assessment bodies, and health authorities to shape value narratives and expectations)
Fractional Leadership
Executive-Level Medical Affairs Leadership
We provide senior-level Medical Affairs leadership to build and steer teams through pivotal growth, rapid development phases or scale ups, launches, organisational transformation or transition periods - ensuring cross functional integration and board-level visibility.
​
Service Menu:
-
Global Medical Planning & Strategy (creation, audit, or revision aligned with R&D and corporate goals)
-
Impact & Value Frameworks (aligned, proprietary models to demonstrate measurable outcomes)
-
Scientific & Medical Communications (scientific platform, publications, congresses, advisory boards, medical information)
-
Integrated Evidence Planning (clinical, real-world, registries, health economics and outcomes research)
-
Impact-Driven Scientific Intelligence (aligning scientific, medical, commercial, and investor perspectives to inform strategy)
-
Patient Advocacy & Disease Awareness (strategic partnerships, disease awareness, external stakeholder alignment)
-
Building & Scaling Medical Affairs Capabilities and Functions depending on Development Phase requirements (capability build, operations, system identification and onboarding, medical excellence)
Strategic Guidance for Funding, Pivots and Acceleration
Transformational Advisory
We advise C-suite leaders and Investors navigating funding decisions, pivots, transformation, or acceleration.
With an objective external perspective and deep scientific expertise, we support due diligence, assess opportunities, resolve barriers, realign strategy, and execute decisive change.
​
Our advisory strengthens confidence at critical inflection points - ensuring that decisions are evidence-based, strategies are future-proofed, and organisations are equipped to move forward with clarity and impact.
​
Service Menu:
-
Investor Due Diligence (target pipeline assessment, risk review, probability of success)
-
Strategic Guidance for Pivots (repositioning or refocusing pipelines)
-
Acceleration Planning (assets and organisations readying for rapid growth)
-
Board-Level Advisory on scientific and corporate alignment
The Lumares Difference
Scientific Insight. Integrated Strategy. Value-led Impact.
Global Leadership & Scientific Authority
Led by a highly published thought leader with global in-house biotech and pharma experience, Lumares Strategy brings a proven record in fast, high- stakes launches and in building and leading Medical Affairs within the R&D organisation from a pre-candidate identification stage through to post-launch.
Cross-Functional Integration and Multi-Stakeholder Corporate Alignment
We embed Medical Affairs and scientific strategy earlier in development to ensure that appropriate data and communications are generated at the right time - mitigating risks that traditional R&D functions cannot identify or anticipate. Drawing from development and launch lessons learned from high-stakes programmes, we embed this experience upstream by working with broader R&D functions, and aligning with Investor Relations, Business Development and Corporate Communications from the outset. This strengthens decision-making and position organisations for success across development milestones.
Proven Advisory & Strategic Impact across Multiple Audiences
We advise executives, boards, and investors at an earlier stage than traditional Medical Affairs involvement — embedding scientific perspective directly into investment strategy, corporate communications, and business development. This early integration ensures that science underpins corporate positioning, builds investor confidence, and strengthens performance across high-stakes decisions.
Client Testimonials
“Lumares Strategy delivered high-level advisory and decisive leadership - transforming our Medical Affairs strategy and accelerating measurable scientific impact.”
- Global BioTech CMO
“Exceptional strategic insight and scientific expertise - instrumental in realigning investor decisions in line with long term with goals and delivering critical outcomes”
- VP, Medical Affairs, Pharma Client
“Board-level advisory that reshaped our approach and drove impactful, science-led results at a pivotal growth stage”
- Founder, Emerging Biotech